In our cohort, IFN is the most common disease-modifying treatment, and although IFN-induced transcriptomic alterations in blood cells of MS patients have been studied previously51–53, DNA methylation changes have not been reported so far. This evidence concerns the gene IFNA1 and myeloid sarcoma.